CT-388

N/A

Report date: 2026/05/26 20:00:28
NME

Base Information

Drug NameCT-388
Drug Alias NameCT-388RG-6640RO7795068RO-7795068
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionGlucagon-like peptide 1 receptor agonistsGlucose-Dependent Insulinotropic Polypeptide Receptor agonists
TargetsGlucagon-like peptide 1 receptorGlucose-Dependent Insulinotropic Polypeptide Receptor
Therapy Area/IndicationsOverweightObesityDiabetes Mellitus, Type 2 +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesTaiwan +[13] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesCarmot Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesCarmot Therapeutics IncF. Hoffmann-La Roche LtdCorden Pharma SPA +[4] 
Inactive CompaniesN/A
Active IndicationsOverweightObesityDiabetes Mellitus, Type 2 +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A